ArticleScientific reports2025
Combined magnetic resonance imaging with serum CA125 for dysmenorrhea in adenomyosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Abnormal expression of galectins and their correlation with fibrogenesis in adenomyosis.Cell adhesion & migration · 2026Article
- MRI-Based Classification Systems Combined with Serum CA125 for Predicting Symptom Recurrence After Ultrasound-Guided High-Intensity Focused Ultrasound Ablation Surgery for Adenomyosis: A Retrospective Cohort Study.International journal of women's health · 2026Article
- Impact of adenomyosis on pregnancy outcomes following frozen embryo transfer: development and validation of a single-center clinical predictive model.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the synergistic predictive capacity of MRI lesion classification and serum CA125 for symptom manifestation (dysmenorrhea/menorrhagia) and explore associated adenomyosis pathogenesis. Patients before focused ultrasound ablation surgery were categorized into MRI-based severity group (Group A) and MRI-based non-severity group (Group B). Binary logistic regression was employed to identify the factors associating dysmenorrhea and CA125 level in total cohort and subgroups via MRI-based classifications criteria. The receiver-operating characteristic (ROC) curve was applied to assess the utility of CA125 for dysmenorrhea. Patients in dysmenorrhea subtype exhibited higher CA125 levels compared with those in non-dysmenorrhea subtype in total cohort and Group A (P < 0.05). Uterine volumes, lesion volumes, CA125 levels and symptom recurrence after FUAS in Group A were shown to be higher than those of Group B. In terms of those with dysmenorrhea, CA125 levels of Group A were shown to be higher when compared with those of Group B (P < 0.05). In Group A, multivariate logistic regression showed that age and CA125 were related to dysmenorrhea in adenomyosis (P < 0.05). CA125 level of 44.8 U/ml was demonstrated as the optimal cut-off point for dysmenorrhea by ROC curves in Group A and total cohort. In relative to patients whose CA125 ≤ 44.8 U/ml, those with CA125 levels﹥44.8 U/ml were more probably to suffer from dysmenorrhea. Furthermore, the multiple regression analysis demonstrated that CA125 level exhibited a positive correlation with the lesion volume and negatively related to age (P < 0.05). Patients with CA125 > 44.8 U/ml were prone to suffer from dysmenorrhea secondary to adenomyosis in MRI-based severity group. Besides, age and the lesion volume were associated with CA125 levels. These findings might offer clues for investigating the pathogenesis of dysmenorrhea and exploring the possible mechanisms with disease progression based on MRI and CA125.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.